CD274 and neoplasm: Roch et al. speculated that evolving sarcopenia is associated with a poor outcome during anti-PD-1/PD-L1 therapy by reflecting an ongoing catabolic process leading to inhibition of many features of antitumor immune response, including CD8+ T-cell migration into tumor microenvironment [34,53].